Breaking News

Immunovative Upgrades Manufacturing Facility

November 26, 2012

Achieves milestone toward commercial cell-based GMP production

Immunovative Therapies, Ltd. (ITL) has completed upgrades to its GMP cell manufacturing facility and GMP operations in Jerusalem to comply with the requirements of advanced clinical trials. The completion and validation of its manufacturing facility will allow the company to launch a Phase II/III trial as planned early in 2013.
The facility upgrades include: two class 10,000 cleanroom facilities, interlocked rooms with increasing levels of pressure and air quality, separate rooms for personnel flow and materials flow, clean space for inventory and finished product storage, and product packaging and shipping. ITL has also completed the Installation Qualification (IQ) validation process for the upgraded facility and the Operation Qualification (OQ) and Performance Qualification (PQ). Once PQ is passed, an initial three trial production run will be conducted. If successful, the facility will be brought on-line in April 2013.
Dr. Michael Har-Noy, founder and chief executive officer of ITL, said, “We are very pleased with the progress for developing new manufacturing technology solutions and the rapid and cost-effect manner in which these technologies are being transferred to the manufacturing floor. We are also pleased that we have been successful in developing technology enabling the economical distribution of our formulated cell products. The investments in R&D and these new GMP manufacturing facilities are consistent with our strategic plan to become the world's leading authority for the mass production and distribution of living cell products."
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research